Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Imatinib Mesylate × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 122 Leukemia 61 Gastrointestinal Stromal Tumors 60 Leukemia, Myeloid, Chronic-Phase 44 Precursor Cell Lymphoblastic Leukemia-Lymphoma 36 Blast Crisis 19 Philadelphia Chromosome 14 Brain Neoplasms 14 Melanoma 12 Neoplasms 11 Neoplasm Metastasis 11 Lung Neoplasms 11 Glioblastoma 11 Leukemia, Myeloid, Acute 10 Leukemia, Myeloid, Accelerated Phase 10 Sarcoma 9 Gliosarcoma 9 Prostatic Neoplasms 8 Leukemia, Myeloid 8 Glioma 8 Central Nervous System Neoplasms 7 Primary Myelofibrosis 6 Oligodendroglioma 6 Dermatofibrosarcoma 6 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Astrocytoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Ovarian Neoplasms 5

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡